Metronomic administration of ibandronate and its anti-angiogenic effects in vitro

Microvascular Research

Volumn 78, Issue 3, 2009, Pages 453-458

  Morgan, Claire ^a   Jeremiah, Steve ^a   Wagstaff, John ^a,b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SINGLETON HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; bFGF; Capillary morphogenesis; Cell growth; Endothelial cells; Ibandronate; Metronomic therapy

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; IBANDRONIC ACID; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CELL PROLIFERATION; CELLS, CULTURED; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71849101017     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2009.07.004     Document Type: Article

References (16)

1. Barrett J., Worth E., Bauss F., et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J. Clin. Pharmacol. 44 (2004) 951-965
2. Daubine F., Le Gall C., Gasser J., et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl. Cancer Inst. 99 (2007) 322-330
3. Ferretti G., Fabi A., Carlini P., et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. Bone 41 (2007) 155-156
4. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62 (2002) 6538-6544
5. Jih Y.J., Lien W.H., Tsai W.C., et al. Distinct regulation of genes by bFGF and VEGF-A in endothelial cells. Angiogenesis 4 (2001) 313-321
6. Kuhn H., Konrad J., Holtz S., et al. Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. Lung Cancer 54 (2006) 149-153
7. Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. European Journal of Cancer Supplements 2 (2004) 9-12
8. Martin T., and Grill V. Bisphosphonates - mechanisms of action. Australian Prescriber 23 (2000) 130-132
9. Michailidou M., Neville-Webbe H., Woodward J., et al. The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro. Heamatologica reports 2 (2006) 48-49
10. Mystakidou K., Stathopoulou E., Parpa E., et al. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. J. Cancer Res. Clin. Oncol. 134 (2008) 1303-1310
11. Santini D., Vincenzi B., Dicuonzo G., et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9 (2003) 2893-2897
12. Santini D., Vincenzi B., Galluzzo S., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13 (2007) 4482-4486
13. Thompson K., Rogers M.J., Coxon F.P., et al. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol. Pharmacol. 69 (2006) 1624-1632
14. Tsai J.C., Goldman C.K., and Gillespie G.Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg. 82 (1995) 864-873
15. Vujasinovic T., Buta M., Markicevic M., et al. Angiogenesis: bFGF and VEGF in breast carcinoma. Arch. Oncol. 14 (2006) 126-130
16. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302 (2002) 1055-1061